Royal Bank of Canada
PTCT icon

Royal Bank of Canada’s PTC Therapeutics PTCT Stock Holding History

Royal Bank of Canada’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,800
Closed -$752K – 7812
2021
Q2 		$752K Buy
+17,800
New +$763K ﹤0.01% 3914

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Royal Bank of Canada's PTCT Position: Q1 2026 in Review

Royal Bank of Canada reduced its PTC Therapeutics (PTCT) stake by 38% in Q1 2026, selling an estimated $168K and leaving 3,863 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #4538.

Royal Bank of Canada first reported a position in PTCT in Q3 2013 and has held it in 51 quarters since. The position peaked at $13.3M in Q2 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Royal Bank of Canada held 3,863 shares of PTC Therapeutics worth $263K as of Q1 2026.
  • Royal Bank of Canada sold 2,378 PTC Therapeutics shares in Q1 2026, an estimated $168K.
  • PTC Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4538 holding.
  • Royal Bank of Canada first reported a position in PTC Therapeutics in Q3 2013 and has held it in 51 quarters since.
  • Royal Bank of Canada's PTC Therapeutics position peaked at $13.3M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.